''Aberman has said Pluristem is in talks with large pharmaceutical companies in the United States, Europe and Japan to market the treatment though he would not disclose names.
"We have a lot of interest," he said. (Editing by Mike Nesbit) ''
http://www.reuters.com/article/idUSLDE70H14820110118?feedType=RSS&feedName=rbssHealthcareNews&rpc=43
weee